TCO89 Antibody

What is TCO89 and why is it important in cellular research?

TCO89 is a unique and essential component of the Target of Rapamycin Complex 1 (TORC1) in yeast Saccharomyces cerevisiae. It plays a crucial role in regulating cellular processes in response to nutrient availability. Unlike other TORC1 components, TCO89 has specific functions in pathways such as the vacuole import and degradation (Vid) pathway, which is responsible for selective degradation of proteins like fructose-1,6-bisphosphatase (FBPase) during metabolic shifts .

TCO89 is particularly important in research because:

• It represents a unique component of TORC1 not found in TORC2

• Deletion mutants (Δtco89) show distinct phenotypes compared to other TORC1 mutants

• It provides insights into how TORC1 regulates cellular responses to nutrient availability

• It has physical interactions with multiple metabolic enzymes, suggesting a direct role in metabolic regulation

• Understanding TCO89 function can reveal novel aspects of TORC1 signaling conserved across species

How can I detect TCO89 protein in yeast samples?

Detection of TCO89 in yeast samples typically involves epitope tagging followed by immunoprecipitation and Western blotting techniques. Based on established protocols:

• Epitope tagging: Generate strains expressing TCO89 with a C-terminal or N-terminal tag (FLAG, HA, or GFP tags are commonly used)

• Cell lysis: Grow cells to log phase, filter and flash freeze, then lyse using appropriate buffers

• Crosslinking: Treat lysates with crosslinkers like dithiobis(succinimidyl propionate) (DSP) to preserve protein-protein interactions

• Immunoprecipitation: Use antibodies against the epitope tag (anti-FLAG, anti-HA, or anti-GFP)

• Western blotting: Separate proteins by SDS-PAGE, transfer to nitrocellulose, and detect using appropriate antibodies

For optimal results when working with TCO89, many researchers find that:

• Adding the crosslinker DSP improves detection of TORC1 complex components

• Using digitonin as a detergent helps maintain complex integrity

• Including phosphatase inhibitors is essential to preserve phosphorylation states

• Normalizing to an internal control like PGK1 improves quantitative comparisons

What antibody dilutions are recommended for TCO89 detection in Western blots?

Based on protocols from the literature and standard immunoblotting techniques for TORC1 components, the following antibody dilutions are typically effective:

• For epitope-tagged TCO89:

  • Anti-FLAG monoclonal antibody: 1:1000 dilution

  • Anti-HA monoclonal antibody: 1:2500 dilution

  • Anti-GFP polyclonal antibody: 1:2500 dilution

• Secondary antibodies:

  • HRP-conjugated anti-mouse IgG: 1:5000-1:10000 dilution

  • HRP-conjugated anti-rabbit IgG: 1:5000-1:10000 dilution

• Control antibodies:

  • Anti-PGK1 antibody: 1:10000 dilution (loading control)

  • Anti-G6PDH antibody: 1:5000 dilution (alternative loading control)

For optimal results, antibody incubation should be performed in blocking buffer containing 5% non-fat dry milk or 3% BSA in TBS-T, with overnight incubation at 4°C for primary antibodies and 1-hour incubation at room temperature for secondary antibodies.

How can I immunopurify TCO89 to study its interacting partners?

Immunopurification of TCO89 requires careful experimental design to maintain protein-protein interactions while minimizing non-specific binding. Based on successful protocols:

• Strain preparation:

  • Generate yeast strains expressing TCO89 with an epitope tag (FLAG, HA, or GFP)

  • Include a control strain with a different tag (e.g., if using TCO89-FLAG, use TCO89-HA as control)

• Sample preparation:

  • Grow cells to log phase or subject them to specific starvation/stress conditions

  • Rapidly filter and flash freeze cells to preserve in vivo interactions

  • Lyse cells in buffer containing protease inhibitors

• Crosslinking and solubilization:

  • Treat lysates with the crosslinker DSP (12 Å) at a concentration of 2.5 mg/ml

  • Add digitonin (1-2%) as a detergent to solubilize membranes while preserving protein complexes

• Immunopurification:

  • Incubate lysates with anti-tag antibody beads (anti-FLAG, anti-GFP)

  • Wash extensively to remove non-specific binders

  • Elute bound proteins by competitive elution (with FLAG peptide) or by breaking crosslinks

• Analysis:

  • Process samples for mass spectrometry or immunoblotting

  • Consider proteins with at least twofold higher abundance in the true IP versus control IP, and with at least seven peptide spectral maps as potential interactors

This approach has successfully identified TORC1 subunits Kog1, Tor1, and other components as interaction partners of TCO89-related proteins .

What controls should I include when studying TCO89 antibody specificity?

When evaluating TCO89 antibody specificity, several critical controls should be included:

• Genetic controls:

  • Wild-type strain (positive control)

  • Δtco89 deletion strain (negative control to confirm antibody specificity)

  • Strains with known TORC1 mutations (like tor1Δ) for comparison

• Epitope tag controls:

  • Parallel immunoprecipitations of differently tagged versions (e.g., TCO89-FLAG vs. TCO89-HA)

  • Untagged strain processed identically to evaluate background binding

• Sample processing controls:

  • Input samples (pre-immunoprecipitation) to confirm protein expression

  • Intergenic region controls for ChIP experiments to control for immunoprecipitation and DNA purification efficiency

  • Evaluate protein levels in whole cell extracts using anti-PGK1 antibody (1:10000) as loading control

• Specificity validation:

  • Preabsorption of antibody with recombinant antigen

  • Peptide competition assays

  • Comparison of antibody reactivity across multiple experimental conditions

Proper controls ensure that observed signals are specific to TCO89 rather than artifacts of the experimental system or cross-reactivity with other proteins.

How can I optimize TCO89 immunoprecipitation from different subcellular fractions?

Optimization of TCO89 immunoprecipitation from different subcellular fractions requires specific adjustments to standard protocols:

• Differential centrifugation approach:

  • After cell lysis, separate cytosolic (S) and membrane/vesicle (P) fractions using differential centrifugation

  • For cytosolic fractions: centrifuge at 13,000 × g to remove cellular debris and membranes

  • For membrane/vesicle fractions: resuspend pellets in appropriate buffer with detergents

• Buffer modifications for different fractions:

  • Cytosolic fraction: Standard IP buffer with lower detergent concentration

  • Membrane/vesicle fraction: Include digitonin (1-2%) or other mild detergents to solubilize membranes while preserving protein interactions

  • Vacuolar fraction: Include vacuole isolation steps prior to immunoprecipitation

• Crosslinking considerations:

  • For membrane-bound TCO89: Use membrane-permeable crosslinkers like DSP

  • For soluble complexes: Consider formaldehyde crosslinking for reversible interactions

• Fraction-specific controls:

  • For vesicle fractions: Co-IP Vid24 as a marker for Vid vesicles

  • For cytosolic fractions: Monitor FBPase distribution as an indicator of fraction purity

  • For vacuolar fractions: Include vacuolar marker proteins as controls

Studies have shown that TCO89 can be found in different cellular compartments depending on nutrient conditions, with implications for its role in protein trafficking and degradation pathways .

How does rapamycin treatment affect TCO89 antibody-based detection methods?

Rapamycin treatment introduces specific considerations for TCO89 detection using antibody-based methods:

• Complex dissociation effects:

  • Rapamycin inhibits TORC1 by binding to FKBP12 and then to the FRB domain of Tor1/Tor2

  • This can cause conformational changes in TORC1 that may alter epitope accessibility or complex integrity

  • Studies show rapamycin treatment strongly blocks processes dependent on TCO89 function, such as FBPase degradation

• Immunoprecipitation adjustments:

  • Time-course experiments are essential (collect samples at 0, 15, 30, 60 minutes after rapamycin addition)

  • Increased crosslinker concentration may be necessary to capture transient interactions

  • Lower stringency washes can help preserve weakened interactions

• Western blot considerations:

  • Phosphorylation state changes rapidly after rapamycin treatment

  • Consider running parallel phospho-specific detection for TORC1 targets (e.g., Sch9, Rps6)

  • Include multiple time points to capture dynamic changes

• Quantification approaches:

  • Normalize TCO89 levels to stable loading controls unaffected by rapamycin

  • Use NTCB cleavage assay for analyzing Sch9 bandshift as a readout of TORC1 activity

  • Compare results with other TORC1 inhibition methods to distinguish direct from indirect effects

Researchers have observed that rapamycin treatment (200 nM for 5.5 hours) causes significant changes in TORC1-dependent processes , making it a valuable tool for studying TCO89 function despite these technical challenges.

What approaches can help resolve contradictory TCO89 antibody results between different experimental conditions?

When facing contradictory TCO89 antibody results across different experimental conditions, consider these systematic troubleshooting approaches:

• Cell cycle effects analysis:

  • TCO89 function and TORC1 signaling are influenced by cell cycle stage

  • Compare asynchronous cultures to synchronized populations

  • Use flow cytometry to determine cell cycle distribution in your samples

  • Normalize results to account for cell cycle differences between conditions

• Nutrient condition standardization:

  • TORC1 components are highly sensitive to nutrient availability

  • Standardize media preparation, cell density, and starvation protocols

  • Compare one-day versus two-day starvation protocols, which can activate different degradation pathways

  • Document exact timing of nutrient shifts and sample collection

• Strain background validation:

  • Generate new epitope-tagged strains in the same background

  • Confirm phenotypes of deletion strains match published data

  • Sequence verify all constructs used in the study

  • Test multiple clones to rule out suppressor mutations

• Cross-validation with complementary techniques:

  • Compare immunoprecipitation with different epitope tags

  • Use proximity labeling approaches (BioID or APEX) as alternatives

  • Combine with fluorescence microscopy to verify localization patterns

  • Develop in vitro kinase assays to directly measure TORC1 activity

Studies have shown that seemingly contradictory results in TCO89 research often reflect its context-dependent functions in different degradation pathways rather than technical artifacts .

How can I distinguish between direct and indirect TCO89 protein interactions using antibody-based approaches?

Distinguishing direct from indirect TCO89 interactions requires sophisticated experimental approaches:

• Crosslinker strategy variation:

  • Use crosslinkers with different arm lengths (DSP: 12Å; formaldehyde: 2-3Å)

  • Short crosslinkers preferentially capture direct interactions

  • Compare interaction profiles with and without crosslinking

  • Apply a chemical crosslinking followed by mass spectrometry (XL-MS) approach to map interaction interfaces

• Staged purification approach:

  • Perform tandem affinity purification with different tags on TCO89 and putative interactors

  • Identify proteins that co-purify under increasingly stringent conditions

  • Use two-step immunoprecipitation protocols to enrich for direct binding partners

• In vitro binding assays:

  • Express recombinant TCO89 or fragments thereof

  • Perform direct binding assays with purified candidate interactors

  • Compare binding efficiency with mutant versions of TCO89

  • Correlate interaction strength with functional outcomes in vivo

• Proximity-dependent labeling:

  • Generate TCO89 fusions with BioID or APEX2

  • Identify proteins that are labeled in living cells

  • Analyze labeling patterns under different conditions (e.g., ± rapamycin)

  • Compare with conventional immunoprecipitation results

Research has shown that TCO89 physically associates with FBPase, and that the P1S mutation of FBPase, which blocks its degradation, impairs this association—suggesting a direct functional interaction .

How should I interpret changes in TCO89 levels versus changes in its post-translational modifications?

Interpreting changes in TCO89 protein levels versus post-translational modifications requires careful experimental design and analysis:

• Distinguishing expression from modification changes:

  • Run parallel samples on different gel systems (standard SDS-PAGE vs. Phos-tag gels)

  • Use total protein detection alongside modification-specific antibodies

  • Monitor mRNA levels via RT-qPCR to identify transcriptional regulation

  • Compare tagged and untagged versions to rule out tag-specific effects

• Phosphorylation analysis approaches:

  • Treat samples with phosphatases to collapse multiple bands into single species

  • Use Sch9 bandshift assays as readouts of TORC1 activity

  • Apply the NTCB cleavage method to analyze phosphorylation patterns

  • Compare phosphorylation patterns with known TORC1 substrates

• Timepoint considerations:

  • TORC1 signaling responds rapidly to stimuli (within minutes)

  • Include early timepoints (5, 15, 30 minutes) to capture initial responses

  • Include later timepoints (1, 2, 4 hours) to capture adaptive responses

  • Consider rapid sample collection methods like filtration and flash freezing

• Integration with known TORC1 readouts:

  • Monitor Rps6 phosphorylation as a standard TORC1 activity readout

  • Compare TCO89 changes with Tor1, Kog1, and other TORC1 components

  • Correlate with downstream phenotypes like cell growth rate or FBPase degradation

Studies have demonstrated that TCO89 protein levels may remain relatively stable even when its functional state changes dramatically, highlighting the importance of analyzing post-translational modifications and protein-protein interactions .

What are the common pitfalls in TCO89 antibody-based chromatin immunoprecipitation (ChIP) experiments?

Chromatin immunoprecipitation using TCO89 antibodies presents several technical challenges that must be addressed:

• Crosslinking optimization:

  • Standard ChIP protocols often use 1% formaldehyde for 10-15 minutes

  • For TCO89 ChIP, crosslinking conditions may need optimization

  • Test different crosslinking times (5-20 minutes) and formaldehyde concentrations (0.75-1.5%)

  • Consider dual crosslinking with DSP followed by formaldehyde for protein-protein and protein-DNA interactions

• Control selection:

  • Include intergenic regions on Chromosome V as negative controls

  • Use known TORC1-regulated promoters as positive controls

  • Include input samples and mock IP controls (e.g., non-specific IgG)

  • Process Δtco89 strains in parallel to identify background signals

• Signal-to-noise optimization:

  • Increase wash stringency gradually to determine optimal conditions

  • Test different sonication protocols to achieve 200-500bp fragments

  • Pre-clear chromatin with protein A/G beads before antibody addition

  • Use competitor DNA (salmon sperm DNA) to reduce non-specific binding

• Data normalization approaches:

  • Normalize to input DNA for each primer pair

  • Further normalize to an intergenic region to control for immunoprecipitation efficiency

  • Compare results between different antibody lots and epitope tags

  • Consider spike-in controls for absolute quantification

Researchers studying histone modifications regulated by TORC1 pathways have developed effective ChIP protocols that can be adapted for TCO89 studies by appropriately modifying crosslinking and immunoprecipitation conditions .

How do I reconcile differences between biochemical data and genetic phenotypes in TCO89 studies?

Reconciling biochemical data with genetic phenotypes in TCO89 research requires systematic analysis:

• Context-dependent function analysis:

  • Compare phenotypes across multiple growth conditions (rich media, different carbon sources, nitrogen limitation)

  • Examine acute versus chronic responses to nutrient deprivation

  • Test rapamycin sensitivity at different concentrations and durations

  • Consider that TCO89 functions in multiple pathways with distinct genetic requirements

• Redundancy examination:

  • Generate double mutants with genes in parallel pathways

  • Test for synthetic interactions with other TORC1 components

  • Compare Δtco89 phenotypes with Δtor1 and Δtco89 Δtor1 double mutants

  • Examine compensation mechanisms that may mask phenotypes in single mutants

• Quantitative correlation approaches:

  • Plot biochemical measurements against phenotypic outcomes

  • Use dose-response relationships to identify thresholds

  • Apply mathematical modeling to predict genetic interactions

  • Measure dynamic responses rather than endpoint measurements

• Direct mechanistic testing:

  • Test whether Δtco89 effects on FBPase degradation correlate with physical interactions

  • Examine localization patterns of Vid24 and other pathway components

  • Create separation-of-function mutations in TCO89 to dissect multiple roles

  • Perform epistasis analysis to order gene functions in the pathway

Research has shown that Δtco89 mutants exhibit distinct phenotypes in different degradation pathways (strong block of Vid-dependent degradation but minimal effect on ubiquitin-proteasome degradation), helping reconcile seemingly contradictory results .

What are the best approaches for developing TCO89 antibodies for interspecies cross-reactivity?

Developing TCO89 antibodies with interspecies cross-reactivity requires strategic epitope selection and validation:

• Epitope selection strategy:

  • Perform multiple sequence alignment of TCO89 homologs across species

  • Identify highly conserved regions, particularly in functional domains

  • Avoid regions with high post-translational modification potential

  • Consider structural accessibility of epitopes (using protein structure prediction tools)

• Antibody development approach:

  • Generate both monoclonal and polyclonal antibodies against conserved epitopes

  • Use recombinant protein fragments rather than synthetic peptides when possible

  • Consider immunizing multiple host species to increase diversity of antibody repertoire

  • Screen antibodies against TCO89 from multiple species early in development

• Validation across species:

  • Test antibodies on samples from multiple species (S. cerevisiae, S. pombe, mammalian cells)

  • Include appropriate controls (Δtco89 yeast, CRISPR knockout mammalian cells)

  • Perform immunoprecipitation followed by mass spectrometry to confirm specificity

  • Validate antibody performance in multiple applications (Western blot, IP, IF, ChIP)

• Application-specific optimization:

  • Determine optimal dilutions for each species and application

  • Modify extraction buffers to account for species-specific differences

  • Consider using epitope-tagged versions in parallel for cross-validation

  • Document exact experimental conditions for reproducibility across labs

Research on TORC1 components has demonstrated considerable conservation of structure and function across species, suggesting that carefully designed TCO89 antibodies could have broad research applications.

How can I optimize semi-quantitative versus fully quantitative TCO89 protein analysis?

Optimizing quantitative analysis of TCO89 requires selecting appropriate techniques based on research questions:

• Semi-quantitative Western blot optimization:

  • Use internal loading controls (PGK1, G6PDH) for normalization

  • Include standard curves with known amounts of recombinant protein

  • Ensure signal detection is in the linear range of response

  • Apply image analysis software with background subtraction

• Fully quantitative approaches:

  • Implement SILAC (Stable Isotope Labeling with Amino acids in Cell culture) for MS-based quantification

  • Use Multiple Reaction Monitoring (MRM) mass spectrometry for absolute quantification

  • Apply fluorescence-based detection with directly labeled antibodies

  • Include spike-in standards of known concentration

• Sample preparation considerations:

  • Standardize cell growth, harvesting, and lysis conditions

  • Use rapid sampling techniques like filtration for time-sensitive experiments

  • Include phosphatase inhibitors to preserve modification states

  • Process all comparative samples in parallel

• Data analysis approaches:

  • Apply appropriate statistical tests based on experimental design

  • Use technical and biological replicates to establish variability

  • Consider Bayesian approaches for complex experimental designs

  • Validate findings with orthogonal techniques

For kinase assays measuring TORC1 activity, researchers have developed in vitro systems using semi-intact cells that recapitulate nutrient-responsive TORC1 activation, providing a quantitative readout that correlates with TCO89 function .

What emerging technologies might improve TCO89 protein interaction studies?

Several emerging technologies show promise for advancing TCO89 protein interaction studies:

• Proximity-dependent labeling methods:

  • BioID fusion to TCO89 for identifying neighboring proteins in living cells

  • APEX2 for temporal control of labeling with minute-scale resolution

  • Split-BioID for detecting conditional interactions

  • TurboID for faster labeling kinetics in acute response studies

• Advanced microscopy approaches:

  • Super-resolution microscopy to visualize TCO89 localization at sub-diffraction resolution

  • Single-molecule tracking to monitor TCO89 dynamics in living cells

  • FRET-FLIM to detect direct protein-protein interactions

  • Lattice light-sheet microscopy for long-term imaging with minimal phototoxicity

• Structural biology innovations:

  • Cryo-electron microscopy of intact TORC1 complexes

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) to map interaction interfaces

  • Integrative structural modeling combining multiple data types

  • AlphaFold2-based prediction of TCO89 structure and interactions

• Systems biology approaches:

  • Genome-wide CRISPR screens for TCO89 genetic interactions

  • Metabolomics profiling to correlate TCO89 function with metabolic state

  • Mathematical modeling of TORC1 network dynamics

  • Multi-omics integration to place TCO89 in broader cellular context

Recent advances in in vitro TORC1 kinase assays have already improved our ability to study nutrient-responsive TORC1 activation , and combining these with newer technologies promises to further elucidate TCO89's precise roles in TORC1 signaling.